Lisa A S Walker1, Leila Osman2, Jason A Berard3, Laura M Rees4, Mark S Freedman5, Heather MacLean5, Denis Cousineau6. 1. University of Ottawa Brain and Mind Research Institute, Canada; The Ottawa Hospital Research Institute, Canada; University of Ottawa, Faculty of Medicine, Canada; University of Ottawa, School of Psychology, Canada; Carleton University, Department of Psychology, Canada; Carleton University, Institute of Cognitive Science, Canada. Electronic address: lwalker@toh.on.ca. 2. University of Ottawa Brain and Mind Research Institute, Canada; St. Paul University, Canada. 3. The Ottawa Hospital Research Institute, Canada; University of Ottawa, School of Psychology, Canada. 4. University of Ottawa Brain and Mind Research Institute, Canada; The Ottawa Hospital Research Institute, Canada; University of Ottawa, School of Psychology, Canada; Carleton University, Department of Psychology, Canada. 5. University of Ottawa Brain and Mind Research Institute, Canada; The Ottawa Hospital Research Institute, Canada; University of Ottawa, Faculty of Medicine, Canada. 6. University of Ottawa, School of Psychology, Canada.
Abstract
BACKGROUND: Given the high prevalence of cognitive dysfunction in people with multiple sclerosis (PWMS) and the lack of availability of specialized neuropsychological services in most MS Clinics, there is a need for a brief cognitive monitoring tool that can be easily administered by MS clinic staff. OBJECTIVE: We aimed to establish the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) as a feasible cognitive monitoring tool and provide Canadian data toward the international validation effort. Secondary considerations were to determine if BICAMS correlates with self-reported cognition and predicted vocational status. METHODS: 57 PWMS were matched to 51 healthy controls (age, sex, education). Participants completed the BICAMS battery which includes the Symbol Digit Modalities Test, and the learning trials from the California Verbal Learning Test-II and the Brief Visuospatial Memory Test-Revised. Depression, self-reported cognition, and fatigue were assessed. Participants were re-tested 15.6 (SD 2.0) days later. RESULTS: With impairment defined as "one or more abnormal tests," 57.9% of MS sample was cognitively impaired. Participants were more likely to be impaired on the BVMT-R (43.9%). On the SDMT and CVLT-II, 28.1% and 26.3% of MS participants were impaired. Sensitivity and specificity were highest for the SDMT. The BICAMS was reliable over time (r value range from 0.69 for BVMT-R to 0.87 for SDMT) with the SDMT being most robust. There was no relationship between BICAMS and subjective cognition. The BVMT-R reliably predicted employment. CONCLUSIONS: The BICAMS detected cognitive impairment to a comparable degree to more comprehensive neuropsychological batteries and is a valid measure of cognition in MS. Reliability of components varies, suggesting care be taken when interpreting serial testing results. The BICAMS is a feasible cognitive assessment tool in Canadians and yields comparable results to other cultures.
BACKGROUND: Given the high prevalence of cognitive dysfunction in people with multiple sclerosis (PWMS) and the lack of availability of specialized neuropsychological services in most MS Clinics, there is a need for a brief cognitive monitoring tool that can be easily administered by MS clinic staff. OBJECTIVE: We aimed to establish the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) as a feasible cognitive monitoring tool and provide Canadian data toward the international validation effort. Secondary considerations were to determine if BICAMS correlates with self-reported cognition and predicted vocational status. METHODS: 57 PWMS were matched to 51 healthy controls (age, sex, education). Participants completed the BICAMS battery which includes the Symbol Digit Modalities Test, and the learning trials from the California Verbal Learning Test-II and the Brief Visuospatial Memory Test-Revised. Depression, self-reported cognition, and fatigue were assessed. Participants were re-tested 15.6 (SD 2.0) days later. RESULTS: With impairment defined as "one or more abnormal tests," 57.9% of MS sample was cognitively impaired. Participants were more likely to be impaired on the BVMT-R (43.9%). On the SDMT and CVLT-II, 28.1% and 26.3% of MS participants were impaired. Sensitivity and specificity were highest for the SDMT. The BICAMS was reliable over time (r value range from 0.69 for BVMT-R to 0.87 for SDMT) with the SDMT being most robust. There was no relationship between BICAMS and subjective cognition. The BVMT-R reliably predicted employment. CONCLUSIONS: The BICAMS detected cognitive impairment to a comparable degree to more comprehensive neuropsychological batteries and is a valid measure of cognition in MS. Reliability of components varies, suggesting care be taken when interpreting serial testing results. The BICAMS is a feasible cognitive assessment tool in Canadians and yields comparable results to other cultures.
Authors: Nadina B Lincoln; Lucy E Bradshaw; Cris S Constantinescu; Florence Day; Avril Er Drummond; Deborah Fitzsimmons; Shaun Harris; Alan A Montgomery; Roshan das Nair Journal: Health Technol Assess Date: 2020-01 Impact factor: 4.014
Authors: Anthony Feinstein; Maria Pia Amato; Giampaolo Brichetto; Jeremy Chataway; Nancy Chiaravalloti; Ulrik Dalgas; John DeLuca; Peter Feys; Massimo Filippi; Jennifer Freeman; Cecilia Meza; Matilde Inglese; Robert W Motl; Maria Assunta Rocca; Brian M Sandroff; Amber Salter; Gary Cutter Journal: BMC Neurol Date: 2020-05-22 Impact factor: 2.474
Authors: Marco Aurélio G de Caneda; Daissy Liliana Mora Cuervo; Nathércia Estevam Marinho; Maria Cecília A de Vecino Journal: Dement Neuropsychol Date: 2018 Apr-Jun